Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors.

ABSTRACT:

Importance

Rituximab is approved for the treatment of moderate to severe pemphigus. However, 20% of patients in the RITUX 3 trial relapsed within the first year of treatment.

Objective

To assess the outcome of an additional rituximab infusion at month 6 in patients with pemphigus who were in complete remission (CR) after rituximab regimen but had 1 or more predictors of relapse at month 3.

Design, settings, and participants

This multicenter cohort study was conducted in France from September 2018 to June 2023 to assess patients with newly diagnosed pemphigus who were in CR after treatment with the RITUX 3 regimen but had predictors of relapse at month 3. Relapse factors were a Pemphigus Disease Area Index (PDAI) score of 45 or higher, desmoglein 1 (DSG1) antibodies gr

SUBMITTER: Hebert V 

PROVIDER: S-EPMC11800125 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature